Pliant Therapeutics (PLRX) Price & Analysis

Compare

515 Followers

PLRX Stock Chart & Stats

$1.75

-$0.35(-2.64%)

At close: Jan 08 4:00 PM EST

$1.75

-$0.35(-2.64%)

Day’s Range― - ―

52-Week Range$1.10 - $16.10

Previous CloseN/A

Volume34.91K

Average Volume (3M)581.13K

Market Cap

$100.68M

Enterprise Value-$131.29M

Total Cash (Recent Filing)$262.87M

Total Debt (Recent Filing)$30.02M

Price to Earnings (P/E)―

Beta1.37

Next Earnings

Nov 11, 2025

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.71

Shares Outstanding61,388,153

10 Day Avg. Volume902,150

30 Day Avg. Volume581,135

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.30

Enterprise Value/Revenue-57.84

Enterprise Value/Gross Profit-547.04

Enterprise Value/Ebitda0.65

Forecast

1Y Price Target

$2.68

Price Target Upside53.14% Upside

Rating ConsensusHold

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Cost ManagementThe company largely completed its corporate restructuring, which included a workforce reduction while also implementing other cost-saving measures to extend cash runway.

Financial StabilityPLRX reported a cash position of $264M which should take them through 2028.

Potential PartnershipsPLRX's Ph 1 study for PLN-101095 in oncology remains ongoing with data from the highest dose cohorts expected, and the program could be a source of partnering value.

Bears Say

Market PerformanceAnalyst believes PLRX will remain an underperformer relative to its peers in the coverage universe.

Program SetbacksThe recent discontinuation of the phase 2b BEACON-IPF study is seen as a fundamental setback for bexotegrast.

Regulatory ChallengesManagement reiterated they do not see a path forward in respiratory indications and areas such as liver fibrosis have onerous regulatory requirements.

Pliant Therapeutics News

Buy/Sell: Wall Street’s top 10 stock calls this week

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the...

15d ago

AMD

Align downgraded, NetEase upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

15d ago

ABT

MOS

Pliant Therapeutics downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Pliant Therapeutics (PLRX) to Underweight from Neutral without a price target The firm says the investment...

15d ago

PLRX

Pliant Therapeutics Announces CBO Hans Hull’s Resignation

Pliant Therapeutics ( ($PLRX) ) just unveiled an announcement. On October 20, 2025, Pliant Therapeutics, Inc. announced the...

9h ago

PLRX

Pliant Therapeutics Settles Loan with Oxford Finance

Pliant Therapeutics ( ($PLRX) ) has provided an announcement. On October 14, 2025, Pliant Therapeutics, Inc. completed a...

4d ago

PLRX

Pliant Therapeutics Reports Q2 2025 Financial Results

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

PLRX

Pliant Therapeutics price target raised to $1.70 from $1.50 at Citi

Citi analyst David Lebowitz raised the firm’s price target on Pliant Therapeutics (PLRX) to $1.70 from $1.50 and...

3M ago

PLRX

Pliant Therapeutics price target lowered to $4 from $17 at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $4 from $17...

3M ago

PLRX

Pliant Therapeutics reports Q2 EPS (71c), consensus (68c)

Reports Q2 cash, cash equivalents and short-term investments of $264.4M. The company has discontinued development of bexotegrast in...

3M ago

PLRX

Pliant Therapeutics Approves Key Proposals at Annual Meeting

Pliant Therapeutics ( ($PLRX) ) has issued an announcement. On April 9, 2025, Pliant Therapeutics held its Annual...

5M ago

PLRX

Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties

Analyst Edward Nash of Canaccord Genuity maintained a Hold rating on Pliant Therapeutics (PLRX – Research Report), retaining...

6M ago

PLRX

Cautious Hold Rating for Pliant Therapeutics Amidst Strategic Restructuring and Drug Development Uncertainties

Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Pliant Therapeutics (PLRX – Research Report) on May...

6M ago

PLRX

PLRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pliant Therapeutics, Inc. (PLRX) is scheduled to report 1st quarter earnings on 05/12/2025. Regarding Q1 estimates, Wall Street...

6M ago

PLRX

Pliant Therapeutics Reports Q1 2025 Financial Results

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q1 earnings. Here is a breakdown of the information...

6M ago

PLRX

PLRX FAQ

What was Pliant Therapeutics’s price range in the past 12 months?

Pliant Therapeutics lowest stock price was $1.10 and its highest was $16.10 in the past 12 months.

What is Pliant Therapeutics’s market cap?

Pliant Therapeutics’s market cap is $100.68M.

When is Pliant Therapeutics’s upcoming earnings report date?

Pliant Therapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 17 days.

How were Pliant Therapeutics’s earnings last quarter?

Pliant Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.677 by -$0.033.

Is Pliant Therapeutics overvalued?

According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pliant Therapeutics pay dividends?

Pliant Therapeutics does not currently pay dividends.

What is Pliant Therapeutics’s EPS estimate?

Pliant Therapeutics’s EPS estimate is -0.52.

How many shares outstanding does Pliant Therapeutics have?

Pliant Therapeutics has 61,388,153 shares outstanding.

What happened to Pliant Therapeutics’s price movement after its last earnings report?

Pliant Therapeutics reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.677. Following the earnings report the stock price went down -1.19%.

Which hedge fund is a major shareholder of Pliant Therapeutics?

Currently, no hedge funds are holding shares in PLRX

Pliant Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-67.55%

Trailing 12-Months

Asset Growth

-38.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Pliant Therapeutics (PLRX) Earnings & Revenues

Historic Earnings Reports

PLRX Stock 12 Month Forecast

Average Price Target

$2.68

▲(53.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,1.646153846153846,1.8423076923076922,2.0384615384615383,2.2346153846153847,2.4307692307692306,2.626923076923077,2.823076923076923,3.019230769230769,3.2153846153846155,3.4115384615384614,3.6076923076923073,3.8038461538461537,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,1.5446153846153845,1.6392307692307693,1.7338461538461538,1.8284615384615384,1.9230769230769231,2.0176923076923075,2.1123076923076924,2.206923076923077,2.3015384615384615,2.3961538461538465,2.4907692307692306,2.5853846153846156,{"y":2.68,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.45,1.4692307692307691,1.4884615384615385,1.5076923076923077,1.5269230769230768,1.5461538461538462,1.5653846153846154,1.5846153846153845,1.603846153846154,1.623076923076923,1.6423076923076922,1.6615384615384614,1.6807692307692308,{"y":1.7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.86,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >